Beijing Adss Development Co.

EDINBURGH, Scotland, July 31, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it will change its ratio of its American Depositary Shares ("ADSs") to ordinary shares from one (1) ADS representing twenty (20) ordinary shares to one ADS representing two hundred (200) ordinary shares (the "ADS Ratio Change"). The ADS Ratio Change is expected to become effective on August 5th, 2024, U.S. Eastern Time. For the ADS holders, the ADS Ratio Change will have the same effect as a one-for-10 reverse ADS split. The ADS Ratio Change will have no impact on the Company's underlying ordinary shares, and no ordinary shares will be issued or cancelled in connection with the ADS Ratio Change. On the Effective Date, holders of the ADSs will be required to surrender and exchange every ten (10) ADSs then held for one (1) new ADS. The Bank of New York Mellon, as the depositary bank for the Company's ADS program (the "Depositary"), will arrange for the exchange. The ADSs will continue to be traded on Nasdaq Capital Market under the symbol "TCBP." No fractional new ADSs will be issued in connection with the change in the ADS ratio. Instead, fractional entitlements to new ADSs will be aggregated and sold by the Depositary and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes and expenses) will be distributed to the applicable ADS holders by the Depositary. As a result of the ADS Ratio Change, the ADS trading price is expected to increase proportionally, although the Company can give no assurance that the ADS trading price after the ADS Ratio Change will be proportionally equal to or greater than the previous' ADS trading price prior to the change. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company's intent or ability to affect any budget savings or execute on any M&A or capital raising strategy. These statements are based on management's current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this press release, please see the risks and uncertainties identified under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available on the Company's Investor Relations website at and on the SEC website at . All forward-looking statements reflect the Company's beliefs and assumptions only as of the date of this press release. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances. About TC BioPharm (Holdings) PLC TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial in treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide. SOURCE TC BioPharm

SAN MATEO, Calif. and SINGAPORE, June 14, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN” or the “Company”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to change the ratio of the American Depositary Shares (“ADSs”) to its ordinary shares, par value $0.01 per share, from one (1) ADS representing twenty-five (25) ordinary shares to one (1) ADS representing two hundred (200) ordinary shares. For the Company’s existing ADS holders, the change in the ADS ratio will have the same effect as a one-for-eight reverse ADS split. There will be no change to the Company’s ordinary shares. The effect of the ratio change on the ADS trading price on the Nasdaq Capital Market is expected to take place at the opening of trading on July 3, 2024 (U.S. Eastern Time). ADS holders of record on the effective date will not be required to take any action in connection with the ADS ratio change. The exchange of every eight (8) then-held (old) ADSs for one (1) new ADS will occur automatically with the then-held (old) ADSs being cancelled and new ADSs being issued by the depositary bank, in each case as of the effective date for the ADS ratio change, July 3, 2024. The ADSs will continue to be traded on Nasdaq under the symbol “ASLN”. No fractional new ADSs will be issued in connection with the ADS ratio change. Instead, fractional entitlements to new ADSs will be aggregated and sold by the depositary bank and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes and expenses) will be distributed to the applicable ADS holders by the depositary bank. As a result of the ADS ratio change, the ADS price is expected to increase proportionally, although the Company can give no assurance that the trading price of the Company’s ADS price after the ADS ratio change will be equal to or greater than eight (8) times the ADS price before the ADS ratio change. About ASLAN Pharmaceuticals ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is developing eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor in moderate-to-severe atopic dermatitis (AD) with the potential to improve upon current biologics used to treat allergic disease, and has reported positive topline data from a Phase 2b dose-ranging study in moderate-to-severe AD patients. ASLAN is currently investigating eblasakimab in dupilumab-experienced, moderate-to-severe AD patients in the TREK-DX Phase 2 trial, with topline data expected at the end of 2024. ASLAN is also developing farudodstat, a potent oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) as a potential first-in-class treatment for alopecia areata (AA) in a Phase 2a, proof-of-concept trial with an interim readout expected in Q3 2024. ASLAN has teams in San Mateo, California, and in Singapore. For additional information please visit the ASLAN website or follow ASLAN on LinkedIn. Forward looking statements This release contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of the Company. These forward-looking statements may include, but are not limited to, statements regarding the trading price of the Company’s ADSs. The Company’s estimates, projections and other forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations, or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of many risks and uncertainties, which include, unexpected safety or efficacy data observed during preclinical or clinical studies; risks that future clinical trial results may not be consistent with interim, initial or preliminary results or results from prior preclinical studies or clinical trials; clinical site activation rates or clinical trial enrollment rates that are lower than expected; the impact of health epidemics or pandemics, or geopolitical conflicts on the Company’s operations, research and development and clinical trials and potential disruption in the operations and business of third-party manufacturers, contract research organizations, other service providers and collaborators with whom the Company conducts business; general market conditions; changes in the competitive landscape; and the Company’s ability to obtain sufficient financing to fund its strategic and clinical development plans. Other factors that may cause actual results to differ from those expressed or implied in such forward-looking statements are described in the Company’s U.S. Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on April 12, 2024. All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections, and other forward-looking statements. Estimates, projections, and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement. Media and IR contacts Emma ThompsonSpurwing CommunicationsTel: +65 6206 7350 Email: ASLAN@spurwingcomms.comAshley R. RobinsonLifeSci Advisors, LLCTel: +1 (617) 430-7577Email: arr@lifesciadvisors.com

“The company did not feel that the proposed discounts were aligned with its duty to its existing shareholders,” Telix Pharmaceuticals explained of its last-minute decision to pull its Nasdaq listing. Investors celebrating the summer resurgence of biotech IPOs might want to put the champagne back on ice, after Telix Pharmaceuticals made the last-minute decision to pull its own Nasdaq listing. The radiopharma-focused biotech, which has been listed on the Australian Securities Exchange since 2017, had been due to join the Nasdaq this morning. As recently as last week, Telix said it expected the initial offering to stretch to 17 million American depository shares (ADSs), which would bring in $183 million—or $211 million if underwriters took up the option to buy an additional 15% of ADSs. But, in a surprise move, the company announced in a June 14 statement that it is withdrawing its Nasdaq IPO. “Given the proposed Nasdaq listing was not predicated on the need to raise capital, Telix’s management and board of directors have decided not to move forward with the transaction at the terms provided under current market conditions,” the company said in its release. “The company did not feel that the proposed discounts were aligned with its duty to its existing shareholders,” it added. “While this is not our desired outcome, Telix’s strategic objectives must align with our duty to existing shareholders,” Telix Managing Director and Group CEO Christian Behrenbruch, Ph.D., said in the release. “I’d like to thank my team for the personal commitment and incredibly long hours put into this IPO process.” Since Telix first set out its Nasdaq ambitions at the start of the year, the company pointed out that its share price rise had risen from 9.53 Australian dollars to AU$16.46 by market close Wednesday. The biotech attributed this “significant share price appreciation” this year to a number of factors, including positive readouts from its pipeline of radiopharmaceuticals as well as “several successful strategic acquisitions” that included radionuclides company ARTMS and radiopharma biotech QSAM Biosciences along with FDA approval applications for renal cell carcinoma radiodiagnostic Zircaix and prostate cancer imaging agent TLX007-CDx. Alongside the healthy Australian share price, Telix stressed that it is already a “profitable, cash generative company,” which has “sufficient earnings and balance sheet capacity” to deliver on its key goals of launching Zircaix, TLX007-CDx and the brain cancer imaging agent Pixclara in the U.S. Telix’s lead radio antibody-drug conjugate, dubbed TLX591, is currently being examined in a phase 2/3 global study for patients with prostate cancer.  While January and February saw a resurgence of interest in biotechs taking the IPO route, a Fierce Biotech analysis of data from S&P Capital IQ in early May showed that only one of these—CG Oncology—was still trading above its IPO price. However, while the IPO window appeared to close again in the spring, recent weeks have seen a few companies express an interest in a Nasdaq listing. Rapport Therapeutics went public on June 7 at an offer price of $17 per share, and the epilepsy biotech was trading up at $23.05 by market close June 13.